KR101987861B1 - Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 - Google Patents

Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 Download PDF

Info

Publication number
KR101987861B1
KR101987861B1 KR1020147014236A KR20147014236A KR101987861B1 KR 101987861 B1 KR101987861 B1 KR 101987861B1 KR 1020147014236 A KR1020147014236 A KR 1020147014236A KR 20147014236 A KR20147014236 A KR 20147014236A KR 101987861 B1 KR101987861 B1 KR 101987861B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
pyrimidin
hydroxycyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147014236A
Other languages
English (en)
Korean (ko)
Other versions
KR20140097229A (ko
Inventor
피터 쥐. 스미스
Original Assignee
밀레니엄 파머슈티컬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 밀레니엄 파머슈티컬스 인코퍼레이티드 filed Critical 밀레니엄 파머슈티컬스 인코퍼레이티드
Publication of KR20140097229A publication Critical patent/KR20140097229A/ko
Application granted granted Critical
Publication of KR101987861B1 publication Critical patent/KR101987861B1/ko
Assigned to 다케다 야쿠힌 고교 가부시키가이샤 reassignment 다케다 야쿠힌 고교 가부시키가이샤 권리의 전부이전등록 Assignors: 밀레니엄 파머슈티컬스 인코퍼레이티드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147014236A 2011-11-03 2012-11-02 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 Expired - Fee Related KR101987861B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555049P 2011-11-03 2011-11-03
US61/555,049 2011-11-03
PCT/US2012/063382 WO2013067396A2 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Publications (2)

Publication Number Publication Date
KR20140097229A KR20140097229A (ko) 2014-08-06
KR101987861B1 true KR101987861B1 (ko) 2019-06-11

Family

ID=48193039

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014236A Expired - Fee Related KR101987861B1 (ko) 2011-11-03 2012-11-02 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여

Country Status (23)

Country Link
US (2) US8980850B2 (https=)
EP (1) EP2773360B1 (https=)
JP (2) JP6231988B2 (https=)
KR (1) KR101987861B1 (https=)
CN (1) CN104245699B (https=)
AU (1) AU2012321106C1 (https=)
BR (1) BR112014010699B1 (https=)
CA (1) CA2854461C (https=)
EA (1) EA028380B1 (https=)
ES (1) ES2668272T3 (https=)
GE (2) GEP20196940B (https=)
HK (1) HK1201733A1 (https=)
IL (1) IL232353B (https=)
MA (1) MA35662B1 (https=)
MX (1) MX357835B (https=)
MY (1) MY176125A (https=)
PH (1) PH12014501001B1 (https=)
PL (1) PL2773360T3 (https=)
SG (1) SG11201401895WA (https=)
TN (1) TN2014000194A1 (https=)
TR (1) TR201807342T4 (https=)
UA (1) UA114414C2 (https=)
WO (1) WO2013067396A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP6038150B2 (ja) * 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤
EP2764866A1 (en) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
JP2016525531A (ja) * 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性骨髄性白血病及び骨髄異形成症候群の処置のためのアザシチジンと組み合わせたボラセルチブ
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
US10695352B2 (en) * 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
WO2018218119A1 (en) * 2017-05-25 2018-11-29 The Board Of Trustees Of The Leland Stanford Junior University Combination of low dose il-2 and an inhibitor of treg il-2r desensitization to treat autoimmune and allergic inflammatory diseases
EP3684363A4 (en) * 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
US20220017908A1 (en) * 2018-11-20 2022-01-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
CA3133751A1 (en) 2019-03-15 2020-09-24 Fulcrum Therapeutics, Inc. Macrocyclic azolopyridine derivatives as eed and prc2 modulators
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
WO2023242235A1 (en) * 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115007323B (zh) * 2022-06-17 2024-01-23 中南大学 一种抑制矿物中黄铁矿浮选的方法
EP4554608A1 (en) * 2022-07-11 2025-05-21 Westlake University Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019124A1 (en) 2006-08-08 2008-02-14 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of e1 activating enzymes
US20100292177A1 (en) 2009-03-23 2010-11-18 Armstrong Robert C Methods of treatment using combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
RS52458B (sr) 2005-02-04 2013-02-28 Millennium Pharmaceuticals Inc. Inhibitori e1 aktivirajućih enzima
EA024006B1 (ru) 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
EP2211870A1 (en) 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
EP2257310A2 (en) * 2008-02-26 2010-12-08 Nerviano Medical Sciences S.r.l. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
NZ589719A (en) * 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019124A1 (en) 2006-08-08 2008-02-14 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of e1 activating enzymes
US20100292177A1 (en) 2009-03-23 2010-11-18 Armstrong Robert C Methods of treatment using combination therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Current Opinion in Oncology, 20(6), 705-710, 2008.
Expert Opinion on Therapeutic Targets, 15(3), 253-264, 2011.

Also Published As

Publication number Publication date
UA114414C2 (uk) 2017-06-12
AU2012321106A1 (en) 2013-05-23
TN2014000194A1 (en) 2015-09-30
MX2014005323A (es) 2014-06-05
CA2854461A1 (en) 2013-05-10
ES2668272T3 (es) 2018-05-17
MA35662B1 (fr) 2014-11-01
WO2013067396A3 (en) 2014-10-16
IL232353B (en) 2018-11-29
WO2013067396A2 (en) 2013-05-10
GEAP201813483A (en) 2018-09-10
PH12014501001A1 (en) 2014-06-09
CN104245699A (zh) 2014-12-24
US20150366886A1 (en) 2015-12-24
BR112014010699A2 (pt) 2017-04-25
GEP20186940B (en) 2019-01-10
KR20140097229A (ko) 2014-08-06
BR112014010699B1 (pt) 2020-12-15
JP2018009035A (ja) 2018-01-18
EP2773360A2 (en) 2014-09-10
HK1201733A1 (en) 2015-09-11
EA028380B1 (ru) 2017-11-30
MX357835B (es) 2018-07-26
GEP20196940B (en) 2019-01-10
US20130116208A1 (en) 2013-05-09
JP2015505816A (ja) 2015-02-26
PH12014501001B1 (en) 2018-05-04
PL2773360T3 (pl) 2018-09-28
AU2012321106B2 (en) 2016-08-04
IL232353A0 (en) 2014-06-30
US8980850B2 (en) 2015-03-17
EA201400539A1 (ru) 2014-12-30
NZ624881A (en) 2016-10-28
EP2773360A4 (en) 2015-09-23
MY176125A (en) 2020-07-24
SG11201401895WA (en) 2014-05-29
TR201807342T4 (tr) 2018-06-21
CN104245699B (zh) 2017-06-27
EP2773360B1 (en) 2018-02-28
CA2854461C (en) 2021-01-19
AU2012321106C1 (en) 2016-11-24
JP6231988B2 (ja) 2017-11-15

Similar Documents

Publication Publication Date Title
KR101987861B1 (ko) Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
RU2737496C2 (ru) Способы лечения рака
JP2024012493A (ja) 消化管間質腫瘍の治療のための併用療法
US20160129003A1 (en) Pharmaceutical Combinations
KR102175622B1 (ko) 마이봄 기능부전의 치료제
KR20160135230A (ko) 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도
CN112165945A (zh) 治疗淋巴样恶性疾病之方法
KR20230113594A (ko) Pik3ca 돌연변이 암을 치료하기 위한 병용 요법
AU2012307309A1 (en) Compositions and methods for treating cancer using PI3K beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
EP2648729A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
EA020046B1 (ru) Фармацевтическая комбинация
AU2014279721A1 (en) Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent
KR20160101027A (ko) 제약 조합물
CN117769416A (zh) Bak激活剂、药物组合物和在治疗癌症中的用途
TW201315471A (zh) 使用ＰＩ３Ｋβ抑制劑及包括ＭＥＫ及ＲＡＦ抑制劑之ＭＡＰＫ通道抑制劑之供治療癌症之組合物及方法
OA16757A (en) Compositions and methods for treating cancer using P13K beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors.
WO2015105822A1 (en) Cancer treatment method
JP2016518400A (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220605

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220605